tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schmidt LE et al. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. 2003 Transplantation pmid:12883193
Albano L et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. 2013 Transplantation pmid:23982340
Troppmann C et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. 2003 Transplantation pmid:12883205
Therapondos G et al. Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? 2003 Transplantation pmid:12883220
Marcos A et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. 2004 Transplantation pmid:15480160
Mentzer RM et al. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. 1998 Transplantation pmid:9448154
Ernst A et al. Lung abcess complicating Legionella micdadei pneumonia in an adult liver transplant recipient: case report and review. 1998 Transplantation pmid:9448158
Cavaillé-Coll MW and Elashoff MR Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. 1998 Transplantation pmid:9448161
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Méndez A et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. 2014 Transplantation pmid:24492423
Moss MC et al. Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? 2014 Transplantation pmid:24492429
Boleslawski E et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. 2004 Transplantation pmid:15223897
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Boldt A et al. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. 2006 Transplantation pmid:16906043
Narayanan M et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. 2013 Transplantation pmid:23423268
Reutzel-Selke A et al. Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. 2003 Transplantation pmid:12811235
Gaber AO et al. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. 2013 Transplantation pmid:23423269
Molano RD et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. 2003 Transplantation pmid:12811239
Guethoff S et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. 2013 Transplantation pmid:23423270
Miyakoshi S et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. 2007 Transplantation pmid:17700155
Huang E et al. Alemtuzumab induction in deceased donor kidney transplantation. 2007 Transplantation pmid:17984833
Jain A et al. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. 2014 Transplantation pmid:25285953
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
Egeland EJ et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. 2017 Transplantation pmid:28452920
Gonwa TA et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. 2001 Transplantation pmid:11773892
Hsiau M et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. 2011 Transplantation pmid:21857278
Fisher RA et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. 1998 Transplantation pmid:9884248
Yates CJ et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. 2013 Transplantation pmid:23902993
Kitayama T et al. Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. 2003 Transplantation pmid:12605126
Egidi MF and Gaber AO Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2003 Transplantation pmid:12605133
Guo Z et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. 1997 Transplantation pmid:9075844
Ciancio G et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. 1997 Transplantation pmid:9075856
Platz KP et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518975
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. 2011 Transplantation pmid:21107305
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Starzl TE et al. Hepatotrophic effects of FK506 in dogs. 1991 Transplantation pmid:1702912
Camirand G et al. Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. 2001 Transplantation pmid:11468532
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Squifflet JP et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. 2001 Transplantation pmid:11468536
Yu S et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. 2006 Transplantation pmid:16421475
Theruvath TP et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. 2001 Transplantation pmid:11468538
Jurcevic S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. 1998 Transplantation pmid:9603168
Borrows R et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. 2006 Transplantation pmid:16421488
Kung L and Halloran PF Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. 2000 Transplantation pmid:10933159
Beatty PR et al. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. 1998 Transplantation pmid:9603175
Arzouk N et al. Interaction between tacrolimus and fumagillin in two kidney transplant recipients. 2006 Transplantation pmid:16421493
Zervos XA et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplantation pmid:9583863
Macphee IA et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. 2002 Transplantation pmid:12490779
Maes BD et al. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. 1999 Transplantation pmid:10589943
Shapiro AM et al. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. 2002 Transplantation pmid:12490784
Mehra MR et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. 2002 Transplantation pmid:12490790
Luan FL et al. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. 2011 Transplantation pmid:21242885
Shaffer D et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). 1995 Transplantation pmid:7535958
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Ahsan N et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. 2001 Transplantation pmid:11477347
Andries S et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. 2001 Transplantation pmid:11477351
Ho ET et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. 2013 Transplantation pmid:23542469
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Veroux M et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. 2012 Transplantation pmid:22298033
Naesens M et al. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. 2008 Transplantation pmid:18431234
Dean PG et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. 2008 Transplantation pmid:18431244
Shoji T et al. Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. 2007 Transplantation pmid:18091523
Roelen DL et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. 1993 Transplantation pmid:7687397
Panz VR et al. Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. 2002 Transplantation pmid:11889436
Charney DA et al. Plasma cell-rich acute renal allograft rejection. 1999 Transplantation pmid:10515379
Fisher NC et al. The clinical impact of nephrotoxicity in liver transplantation. 2000 Transplantation pmid:10910259
MacDonald AS Management strategies for nephrotoxicity. 2000 Transplantation pmid:10910262
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Reyes J et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. 2000 Transplantation pmid:10910279
Moffatt SD and Metcalfe SM Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. 2000 Transplantation pmid:10836388
Randhawa PS et al. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. 1999 Transplantation pmid:9921801
Higgins RM et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10836393
Meiser BM The best dosing for initial tacrolimus application is trough level adapted! 2005 Transplantation pmid:15714162
Podesser BK et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. 2005 Transplantation pmid:15714171
Garton T Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. 2002 Transplantation pmid:12352898
Cantarovich D et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. 2005 Transplantation pmid:15714172
Yamauchi A et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. 2002 Transplantation pmid:12352921
Nguyen L et al. Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. 2012 Transplantation pmid:22960763
Ochiai T et al. Studies of the effects of FK506 on renal allografting in the beagle dog. 1987 Transplantation pmid:2447688
Thomas PG et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. 2007 Transplantation pmid:17565326
Ochiai T et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. 1987 Transplantation pmid:2447689
Inamura N et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. 1988 Transplantation pmid:2447690
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Peng Y et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. 2013 Transplantation pmid:23263506
Kuypers DR et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. 2013 Transplantation pmid:23263559
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
White M et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. 2006 Transplantation pmid:17006323
Katz IA et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. 1991 Transplantation pmid:1716801
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Hricik DE et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2003 Transplantation pmid:14508357
Foster RD et al. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. 2003 Transplantation pmid:14508367
Chan L et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. 2010 Transplantation pmid:20517177
Hodak SP et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. 1998 Transplantation pmid:9734501